Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=C7197606
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Antibody therapies for the treatment of COVID-19
#MMPMIDC7197606
Ku Z
; Ye X
; Toa Salazar G
; Zhang N
; An Z
Antib Ther
2020[Apr]; ? (?): ? PMIDC7197606
show ga
: An outbreak of COVID-19, the disease caused by infection of the coronavirus
SARS-CoV-2, that began in December 2019 in Wuhan, China has caused more than
2,990,559 confirmed human infections and 207,446 deaths as of April 27, 2020
(Coronavirus COVID-19 Global Cases by the Center for Systems Science and
Engineering (CSSE) at Johns Hopkins University). Scientists are working quickly
on multiple aspects of the pandemic. Genetic analyses are conducted to reveal the
source and evolution of SARS-CoV-2, providing knowledge that can be used to
contain it and to avoid future outbreaks. Epidemiological studies which
incorporates lessons learned from outbreaks of previous related viral diseases
can guide development of public health measures effective to contain the current
and future outbreaks. Basic virology studies reveal viral structure and function.
Pathology studies inform development of strategies to interfere with infection.
COVID-19 prevention and treatment strategies are being developed in preclinical
and clinical studies. Antibody-based therapy is one viable treatment option.
Here, we discuss some of the most active areas of developing strategies to treat
COVID-19, focusing on approaches to generate neutralizing antibodies against
SARS-CoV-2 for prophylactic and therapeutic treatment of COVID-19. SIGNIFICANCE:
Development of SARS-CoV-2 neutralizing antibodies with the desired efficacy and
safety profile is a critical part of the toolbox of therapies for the treatment
of COVID-19. We discuss in this review the current state of discovery and
development of such antibodies.
free
free
free
